Renal adenocarcinoma cell line Renca was purchased from the American Type Culture Collection (ATCC). Tumor cells were maintained in RPMI-1640 (Microgem), supplemented with 10% fetal bovine serum (FBS; Microgem). The Renca-Luc variant was obtained by infecting Renca cells with a lentiviral vector carrying the coding sequence of synthetic firefly luciferase gene luc2 and using blasticidin (5 µg mL−1; Gibco) as a selection antibiotic. The Renca-iRFP670 is the fluorescent Renca variant stably expressing the iRFP670 fluorescent protein. The UV-2237 fibrosarcoma cell line26 (link) was maintained in DMEM (EuroClone) supplemented with 10% FBS. Stocks of the cell lines were stored frozen in liquid nitrogen and used within four weeks after thawing. Cells were routinely tested by PCR for Mycoplasma contamination.
The Lewis Lung carcinoma cell line (LLC) was obtained from the Developmental Therapeutics Program (DTP) – Division of Cancer Treatment and Diagnosis (DCTD) Tumor Repository, NCI, US. LLC was stocked frozen as in vivo-derived tumor fragments and maintained subcutaneously in C57/BL6 mice before testing.
The Lewis Lung carcinoma cell line (LLC) was obtained from the Developmental Therapeutics Program (DTP) – Division of Cancer Treatment and Diagnosis (DCTD) Tumor Repository, NCI, US. LLC was stocked frozen as in vivo-derived tumor fragments and maintained subcutaneously in C57/BL6 mice before testing.